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Medication Safety Alert | AKUH Un-fractioned
Heparin Usage Guideline for Systemic
Anticoagulation in Adults
Hafsah M. Ashfaq, Pharmacist

High alert medications are an essential component of drug therapy, but
they carry a significant risk of causing serious injuries or death to patients
if used in error. Anticoagulants are also among “High Alert Medications.”
Unfractionated heparin, low-molecular weight heparin, and warfarin
are the frequently used anticoagulants. When used or omitted in error,
anticoagulants can cause life-threatening or fatal bleeding or thrombosis.
The Aga Khan University hospital developed guideline that is
implemented in all the patient care areas including ER in order to
standardize the usage and monitoring of Heparin. The highlights of
guideline are as follows:
Prepare
dilution,
25,000 units
heparin/ 500
ml D5W and
NS

Obtain
baseline
aPTT,
CBC and
Cr

Perform
Bleeding
Risk
assessment
(anx. 1.1
available in
the policy )

Calculate
maintenance
dose/ IV
infusion
(according to
condition)

Calculate
initial dose/
bolus if
required
(according
to condition)

Check aPTT
Q6h till 2
consecutive
goal readings
achieved

Obtain aPTT
after 6 hrs.
adjust by
Nomogram
(Standard &
Low traget
Nomogram)

Monitor
aPTT daily
and platelet
counts
every 3rd
Day.

Flow Chart for Heparin Protocol:
Consult hematologist before starting Heparin if:
l
Epidural catheter in place
l
Platelets < 50x109/L
l
aPTT > 79 seconds
l
DIC, TTP or HIT
l
Active bleeding
Bolus:
DVT/PE = 80 units/kg IV push (rounded to nearest 1000) Max. Dose =
10,000 units.
TIA, ACS, MI & ischemic CVA = 60 units/kg IV push (rounded to nearest
1000) Max. Dose= 5000 units.
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Infusion:
DVT/PE = 18 units/kg/hr (Max initial rate is 2250 units/hr)
TIA, ACS, MI & ischemic CVA = 12 units/kg/hr (Max initial rate is 1000 units/hr)
Goal of Therapy/Target:
Until target aPTT is reached, labs are checked every 3-6 hours as per nomogram and corresponding dose is
adjusted or hold as applicable.
a. Standard Target indications (aPTT 50-80 sec):
Atrial fibrillation, VTE (DVT/PE), Arterial thromboembolism, Peripheral vascular disease, Mechanical valve.
b. Low Target Indications (aPTT 50-60 sec):
Patients > 70 years of age, pulmonary hypertension, ischemic stroke in patients with atrial fibrillation, patients
with ACS, patients receiving GPIIb-IIIa inhibitors or fibrinolytics.
Alerts:

Bleeding risk assessment is to be done by resident before starting therapy
l
Resident of a primary team will review heparin infusion order as per protocol (6hrly/ 3hrly)
l
Nurse will document the Date, Time of aPTT test & result on Heparin Infusion protocol worksheet as
		 per protocol (6hrly/ 3hrly). A nurse signature is required on the worksheet
l
Any adjustment in dose will be done by resident of a primary team only. A resident signature is 		
		 required on the worksheet
l
If aPTT >120 sec nurse will hold infusion and immediately inform resident and/or senior resident of a
		primary team.
l
Recommended lab monitoring is to be done (aPTT daily 6 hrly, Platelets count every 3rd day)
l
Clinical monitoring (bruises, bleeding, hematoma, neurological status); every shift
l
Follow guideline while switching Heparin to/from other anticoagulants (Warfarin, Enoxaparin, 		
		 Fondaparinux, Rivaroxaban etc.). Gap of required hours must be maintained
l
Pharmacy will ensure that 2 anticoagulants are not dispensed together to the same patient
l
Avoid concomitant LMWH administration
l
Physician should delay heparin order as per below mentioned conditions. In case of deviation, 		
		 attending physician and/or team resident will contact pharmacy directly:
		P Tirofiban given in less than last 4-8 hrs
		P LMWH given in less than last 6 hrs
		P Streptokinase in less than last 24 hrs
		P Alteplase in less than last 24 hrs
l
Infusion will be prepared and dispensed by Pharmacy after checking aPTT.
l
Standard dilution is 25000 units heparin per 500 ml D5W or NS i.e. 50 units/ml
l

Note: The Reversal of Heparin overdose & Transition to other anticoagulants are described in the Heparin
Guidelines. Details will soon be available on: http://portal.aku.edu/jcia/jcia-cpg.asp

3

Pharmacy Newsletter

FDA Drug Safety Podcast of the Year 2014
Sadaf Gul, Pharmacist

S. No.

Date

Drug

1

December 11th

Ziprasidone

Ziprasidone may cause Drug Reaction with Eosinophilia and Systemic
Symptoms (DRESS) which starts with a rash leading to swollen lymph
nodes, high eosinophil counts, inflammation of organs and even death.

2

November 16th

Aspirin +
Prasugrel/Clopidogrel

A Clinical trial is being evaluated which showed 30 months therapy with
dual antiplatelet has decreased risk of heart attacks and clot formation in
stents, but an increased risk of death as compared to 12 months therapy.

3

September 26th

Omalizumab

The warning that Xolair, when used in the treatment of asthma, may
cause problems in the blood vessels supplying to the brain has been added
to the label.

4

June 26th

Lidocaine 2%

A box warning to Oral viscous Lidocaine 2% solution will soon be added
to the label. Its use for teething pain in infants and young children can
cause serious harm, including death.

5

June 25th

Topical Acne
Products

Certain OTC topical acne products can cause rare but potentially lifethreatening allergic reactions or severe irritation. Consumers should seek
medical attention if they experience such reaction.

6

June 24th

Olmesartan

There is no clear evidence of increased cardiovascular risks with the use
of Olmesartan in diabetic patients.

7

June 20th

Docetaxel

The intravenous Docetaxel contains ethanol. Patients may experience
intoxication during and after treatment.

8

June 19th

Testosterone
Products

Manufacturers of Testosterone Products are required to include a general
warning about the risk of venous thromboembolism, including DVT and
PE, on the labels.

9

April 23rd

Corticosteroid

Warnings about serious adverse effects like loss of vision, stroke, paralysis and death with the use of epidural Corticosteroids are to be added to
the label.

10

March 31th

Sildenafil

It was clarified that Sildenafil is approved to treat Pulmonary Arterial
Hypertension in adults, not in children.

11

January 31st

Testosterone Products

Risk of stroke, heart attack, and death with use of FDA
approved testosterone products is being investigated.

12

January 8th

Sodium Phosphate Drugs

More than one dose of Sodium Phosphate in a day can cause harm to the
kidneys, heart, and even death. High Risk Patients: Children under 5
(Oral form), under 2 years (Rectal Form), > 55 years old; Dehydrated, renal compromised, Bowel Obstruction/inflamed and those on nephrotoxic
drugs (NSAID, ARBs, ACEI, etc.)

The Podcast

Reference: http://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/
*Table includes only the podcast of those drugs available at local market.
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Resuscitation Fluids in Critical Illness
Kashif Hussain, Clinical Specialist

Resuscitation fluids may be the most common intervention in critical car. However, there is scarce evidence to
guide the best use of resuscitation fluids in the ICU.
Resuscitation Fluids in the ICU: Pearls
l
There is no such thing as an ideal resuscitation fluid; they each have flaws, and none has been 		
		 demonstrated superior to the others in effectiveness or safety.
l
Any resuscitation fluid can contribute to interstitial edema, which may have detrimental effects on
		 ventilator weaning, cardiovascular function, wound healing, or other outcomes.
l
Although colloids have been believed to have superior “volume-expanding” effects over crystalloids,
		 any advantage of colloids in hemodynamic response appears to be minimal in practice.
l
Normal saline given in large quantities can cause a hyperchloremic metabolic acidosis, and has been
		 associated with renal injury.
l
Hydroxyethyl starches (HES) have harmful effects in many critically ill patients, and there seems to be
		 little justification for their continued use, or for other semisynthetic colloid solutions.
l
Albumin appears safe and may be helpful in early sepsis, but has no definite advantages, and is too
		 expensive to recommend as a standard resuscitation fluid.
l
Hypertonic saline (used to avoid producing edema) has not yet been proven safe.
Saline is Not Normal (But it is cheap and effective)
Saline’s designation as “normal” was based on an erroneous calculation of the salt concentration in blood as
0.9% back in 1882 (it’s actually 0.6%). Saline is nearly isotonic with extracellular fluid, but frequently causes
a hyperchloremic metabolic acidosis; the excess chloride has been blamed for immune and renal function. It’s
also a common reason for hypernatremia in hospitalized patients.
However, saline is cheap, and is an effective resuscitation fluid; it’s by far the most widely used globally.
Resuscitation Fluids: What’s inside?
Albumin (20%) Saline (0.9% NaCl) Lactated Ringer’s
Sodium (Na)
145 mmol/L
154 mmol/L
130 mmol/L
Chloride (Cl)
128 mmol/L
154 mmol/L
109 mmol/L
Potassium (K)
none
none
4 mmol/L
Calcium (Ca)
none
none
1.5 mmol/L
Magnesium (Mg)
none
none
none
Lactate
none
none
28 meq (28 mmol/L)
Acetate
none
none
none
Gluconate
none
none
none
Tonicity
250 mOsml/L
308 mOsm/L
280 mOsm/L

Plasma-Lyte
140 mmol/L
98 mmol/L
5 mmol/L
none
3 mmol/L
none
27 mmol/L
23 mmol/L
Isotonic (294 mOsm/L)

Albumin as a Resuscitation Fluid
Albumin has hemodynamic advantages over crystalloid solutions as a volume-expanding resuscitation fluid.
Physiologic studies have suggested a 1:3 ratio of albumin to crystalloid to achieve the same intravascular
volume. Some consider albumin a wise choice as a resuscitation fluid for patients considered to be more at
risk for volume overload (e.g., congestive heart failure, liver failure, or end-stage-renal disease). Given its
narrow margin of benefit, albumin is too expensive to be recommended as a standard resuscitation fluid.
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Operational Quality and Patient Safety Indicators – 2014
Hafsah M. Ashfaq – Pharmacist

The quality indicators are measures of hospital quality and safety drawn from readily available hospital
inpatient data. Hospitals use Quality Indicators (QIs) to identify potential concerns about quality and safety
and track their performance over time. The indicator which Drug & Poison Information Centre (DPIC),
Department of Pharmacy Services, AKUH uses to track the performance includes:
l Renal Dose Adjustment
l Carbapenem Interchange policy
l IV to PO Switch
l Therapeutic Drug Monitoring (TDM) of narrow therapeutic index drugs
l ADR identification through Triggers & Markers
Pharmacist at Drug & poison information center (DPIC) performs these activities daily and intervenes
according to recommendation from different guidelines & resources.
Renal Dose adjustment is a major component of the operational quality indicators. Kidneys are the major
route of elimination for most of the drugs. In patients with renal impairment, CKD or AKI accumulation
of drug metabolites can cause adverse drug reactions, so the dosages must be adjusted according to renal
function.
Patient having deranged creatinine are searched daily and their doses are adjusted according to creatinine
clearance and during the last year 100% interventions accepted for renal dose adjustment.

l

Renal Dose Adjustment
Percentage acceptance
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60%
40%
20%
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Carbapenem interchange policy has been approved by Antibiotics Subcommittee as well as Hospital
Pharmacy and Therapeutic Committee (P & TC), an oversight committee of the Antibiotics Subcommittee.
Primary reasons have been the cost per gram of the Meropenem (estimated savings of Rs.1500-2000 per day
depending on dose), identical and similarity of spectrum and usage in approved indication.

l

Exclusion criteria (Meropenem indication):
l
Pediatric age group
l
Known case of epilepsy or having seizures
l
CNS infections
l
Head trauma/injury (conditions in which seizure threshold may decrease)
All the patients on Meropenem (except the exclusions mentioned above) are reviewed and advised for switching
from Meropenem to Imipenem. Below is the graphical representation of percentage compliance in the Year 2014.

6

Pharmacy Newsletter

Carbapenem Interchange
Percentage compliance
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IV to PO switch is the prompt conversion of IV antibiotic therapy to Oral. Patients may be considered candidates for switching from IV to Oral therapy once the patient has shown clinical improvement and is medically stable. It helps in:

l

l
l
l
l
l

		

Reduction in the likelihood of hospital acquired bacteremia and infected/phlebitic IV lines.
Saves both medical and nursing time
Earlier hospital discharge.
Significantly reduce treatment costs.
Potential reduction in the risk of adverse effects; errors in preparation are significantly higher with
parenteral drugs, compared to oral formulation

Medicines that have more than 80% oral bioavailability are switched from IV to PO.
All the patients on selected drugs are reviewed according to the criteria defined and suggested to shift from
IV to PO route. The graph below shows the compliance rate for the year 2014.

Monthly IV to PO Switch
Compliance (%)
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Therapeutic drug monitoring is necessary for the narrow therapeutic index drugs to evaluate their doses
and therapeutic response. Narrow therapeutic drug have narrow margin of safety so it is recommended to
monitor their serum concentration prior to direct clinical observation. Drugs included in TDM are digoxin,
theophylline, warfarin & Phenytoin. Pharmacists check the profile and if required suggest the physician
for proper time to draw drug levels. Below graph for last year shows the percentage of patients required
interventions for doses to be changed with respect to the serum drug concentrations.

l
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% interventions required monthly
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Triggers and Markers Pharmacy maintains the record of adverse drug reactions reported and takes the
follow up. On monthly basis summary of ADRs is prepared for review by P&TC to take necessary action
for safety. Trigger and markers is an activity in which the tracking of an ADR is done by the stat shots of
particular agents that are used to reduce the adverse effects produced by a certain drug e.g. IV Pheniramine for
an allergic reaction produced by cephalosporin or IV protamine given for heparin overdose etc. Following are
the numbers of ADRs reported to DPIC in year 2014.
l

Adverse Drug Reaction( ADR)
No. of ADRs Reported
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Proud to Report
Polio Eradication Awareness Campaign
2 DROPS OF POLIO VACCINE, EVERY CHILD, EVERY TIME.
POLIO - FREE PAKISTAN : A DREAM MUST COME TRUE!

A PUBLIC SERVICE MESSAGE BY IMMUNIZATION SERVICES, MANAGED BY DEPARTMENT OF PHARMACY, AKUH

Pakistan is amongst the three countries where poliomyelitis (polio) is still categorized as an endemic. WHO advisory in month of April 2014
also impose that every traveler of Pakistan has to be vaccinated with polio vaccine. Department of Pharmacy Services, The Aga Khan University
Hospital started Polio eradication campaign to spread awareness and to encourage public to participate in Government Polio Campaigns.
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Pharmacy Staff Appreciation Evening, 2014

Pharmacy staff appreciation evening 2014 was held on Sunday 1st Feb, 2015 at the Sports and Rehabilitation Centre. At the event various thought
provoking skits, songs and parodies were presented. Awards were distributed to the best nominees & outstanding achievers of 2014. A video title
“Pharmacy achievements 2014” was especially made having the achievements of AKUH Pharmacy in 2014.

Newsletter Feedback

Please help us improve our newsletter by filling the online feedback form through below link:

https://docs.google.com/forms/d/1ic4R7RJZcco6x8zHpFc6PZhM4HpjmDWUcVyRs1yVjzM/viewform?usp=send_form

The Aga Khan University Hospital, Karachi

